Mechanisms of SU5416, an inhibitor of vascular endothelial growth factor receptor, as a radiosensitizer for colon cancer cells

Kim,Eun  Ho; Lee,Hanna; Jeong,Youn  Kyoung; Jung,Won-Gyun

doi:10.3892/or.2016.4868

Mechanisms of SU5416, an inhibitor of vascular endothelial growth factor receptor, as a radiosensitizer for colon cancer cells

Authors:
- Eun Ho Kim
- Hanna Lee
- Youn Kyoung Jeong
- Won-Gyun Jung
View Affiliations

Affiliations: Division of Heavy Ion Clinical Research, Korea Institute of Radiological and Medical Sciences, Nowon-Ku, Seoul 139-706, Republic of Korea, Research Center for Radiotherapy, Korea Institute of Radiological and Medical Sciences, Nowon-Ku, Seoul 139-706, Republic of Korea
Published online on: June 10, 2016 https://doi.org/10.3892/or.2016.4868
Pages: 763-770

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer is one of the most common cancers worldwide. Previous studies suggest that chemoradiotherapy is more effective for the treatment of colorectal cancer than is radiotherapy or chemotherapy alone. To enhance the radiosensitivity of tumor cells, several investigators have used targeted therapeutic agents that act as radiosensitizers. In the present study, we provide a scientific rationale for the clinical application of SU5416, an inhibitor of vascular endothelial growth factor receptor-2, as a radiosensitizer for colorectal cancer. Two human colorectal adenocarcinoma cell lines, HCT116 and HT-29, were treated with SU5416 and radiation alone or radiation followed by SU5416. In vitro tests were performed using colony forming assays, flow cytometric analysis, immunohistochemistry, senescence-associated β-galactosidase, tumor cell motility and invasion assays. The combination of radiation and SU5416 synergistically inhibited cell survival and induced apoptosis through reactive oxygen species, enhanced IR-induced premature senescence, and inhibited DNA repair activity, cell migration and invasion. Collectively, our results favor the use of SU5416 and radiotherapy as a combination therapy for the treatment of colon cancer and it can be combined successfully with a radiation regimen to potentiate its antitumor and antimetastatic activities for future clinical trials.

View Figures

View References

1	Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard JA, et al: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 324:709–715. 1991. View Article : Google Scholar : PubMed/NCBI
2	Seiwert TY, Salama JK and Vokes EE: The concurrent chemoradiation paradigm - general principles. Nat Clin Pract Oncol. 4:86–100. 2007. View Article : Google Scholar : PubMed/NCBI
3	Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marmé D and Lorusso PM: Differentiation and definition of vascular-targeted therapies. Clin Cancer Res. 11:416–420. 2005.PubMed/NCBI
4	Jubb AM, Pham TQ, Hanby AM, Frantz GD, Peale FV, Wu TD, Koeppen HW and Hillan KJ: Expression of vascular endothelial growth factor, hypoxia inducible factor 1α, and carbonic anhydrase IX in human tumours. J Clin Pathol. 57:504–512. 2004. View Article : Google Scholar : PubMed/NCBI
5	Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, et al: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59:99–106. 1999.PubMed/NCBI
6	Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, Gröne HJ, Debus J, Lipson KE and Abdollahi A: Trimodal cancer treatment: Beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res. 65:3643–3655. 2005. View Article : Google Scholar : PubMed/NCBI
7	Bischof M, Abdollahi A, Gong P, Stoffregen C, Lipson KE, Debus JU, Weber KJ and Huber PE: Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. Int J Radiat Oncol Biol Phys. 60:1220–1232. 2004. View Article : Google Scholar : PubMed/NCBI
8	Krystal GW, Honsawek S, Kiewlich D, Liang C, Vasile S, Sun L, McMahon G and Lipson KE: Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res. 61:3660–3668. 2001.PubMed/NCBI
9	Lu B, Geng L, Musiek A, Tan J, Cao C, Donnelly E, McMahon G, Choy H and Hallahan DE: Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium. Int J Radiat Oncol Biol Phys. 58:844–850. 2004. View Article : Google Scholar : PubMed/NCBI
10	Kharbanda S, Saleem A, Shafman T, Emoto Y, Taneja N, Rubin E, Weichselbaum R, Woodgett J, Avruch J, Kyriakis J, et al: Ionizing radiation stimulates a Grb2-mediated association of the stress-activated protein kinase with phosphatidylinositol 3-kinase. J Biol Chem. 270:18871–18874. 1995. View Article : Google Scholar : PubMed/NCBI
11	Leber MF and Efferth T: Molecular principles of cancer invasion and metastasis (Review). Int J Oncol. 34:881–895. 2009.PubMed/NCBI
12	Begg AC, Stewart FA and Vens C: Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 11:239–253. 2011. View Article : Google Scholar : PubMed/NCBI
13	Cherrington JM, Strawn LM and Shawver LK: New paradigms for the treatment of cancer: The role of anti-angiogenesis agents. Adv Cancer Res. 79:1–38. 2000. View Article : Google Scholar : PubMed/NCBI
14	Wachsberger P, Burd R and Dicker AP: Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: Exploring mechanisms of interaction. Clin Cancer Res. 9:1957–1971. 2003.PubMed/NCBI
15	Jain RK, Duda DG, Clark JW and Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 3:24–40. 2006. View Article : Google Scholar : PubMed/NCBI
16	Stadler WM, Heimann R, Karczmar GS, Gajewski T, Kindler H, MacEaneny P, Zamora M, Medved M and Vokes E: Clinical evaluation of tumor angiogenesis markers in metastatic cancer. Proc Am Soc Clin Oncol. 20:3822001.
17	Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A and Huber PE: Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res. 14:2210–2219. 2008. View Article : Google Scholar : PubMed/NCBI
18	Bernier J, Hall EJ and Giaccia A: Radiation oncology: A century of achievements. Nat Rev Cancer. 4:737–747. 2004. View Article : Google Scholar : PubMed/NCBI
19	Brooks PC: Cell adhesion molecules in angiogenesis. Cancer Metastasis Rev. 15:187–194. 1996. View Article : Google Scholar : PubMed/NCBI
20	Basset P, Okada A, Chenard MP, Kannan R, Stoll I, Anglard P, Bellocq JP and Rio MC: Matrix metalloproteinases as stromal effectors of human carcinoma progression: Therapeutic implications. Matrix Biol. 15:535–541. 1997. View Article : Google Scholar : PubMed/NCBI
21	Johnsen M, Lund LR, Rømer J, Almholt K and Danø K: Cancer invasion and tissue remodeling: Common themes in proteolytic matrix degradation. Curr Opin Cell Biol. 10:667–671. 1998. View Article : Google Scholar : PubMed/NCBI
22	Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI